Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$441K Buy
15,691
+2,238
+17% +$59.6K 0.03% 227
2025
Q4
$335K Sell
13,453
-159
-1% -$4.01K 0.02% 288
2025
Q3
$347K Buy
13,612
+543
+4% +$13.4K 0.03% 197
2025
Q2
$317K Buy
13,069
+191
+1% +$4.45K 0.03% 193
2025
Q1
$326K Buy
12,878
+1,694
+15% +$44.3K 0.03% 182
2024
Q4
$297K Sell
11,184
-4,068
-27% -$110K 0.03% 198
2024
Q3
$442K Buy
15,252
+1,987
+15% +$58K 0.04% 196
2024
Q2
$371K Sell
13,265
-827
-6% -$22.8K 0.04% 201
2024
Q1
$391K Sell
14,092
-797
-5% -$22.1K 0.05% 209
2023
Q4
$429K Buy
14,889
+819
+6% +$24.8K 0.06% 182
2023
Q3
$467K Sell
14,070
-5,557
-28% -$197K 0.07% 159
2023
Q2
$720K Buy
19,627
+696
+4% +$27.1K 0.11% 113
2023
Q1
$772K Buy
18,931
+956
+5% +$41.3K 0.13% 100
2022
Q4
$921K Buy
17,975
+1,042
+6% +$50K 0.17% 79
2022
Q3
$741K Buy
16,933
+710
+4% +$34.5K 0.15% 85
2022
Q2
$851K Buy
16,223
+682
+4% +$34.8K 0.18% 70
2022
Q1
$805K Buy
15,541
+3,946
+34% +$205K 0.15% 92
2021
Q4
$685K Buy
+11,595
New +$574K 0.14% 117

Other funds holding PFE

Quent Capital's PFE Position: Q1 2026 in Review

Quent Capital increased its Pfizer (PFE) stake by 17% in Q1 2026, buying an estimated $59.6K and bringing the position to 15,691 shares worth $441K. The position accounts for 0.03% of the portfolio, ranked #227.

Quent Capital first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. The position peaked at $921K in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Quent Capital held 15,691 shares of Pfizer worth $441K as of Q1 2026.
  • Quent Capital bought 2,238 Pfizer shares in Q1 2026, an estimated $59.6K.
  • Pfizer made up 0.03% of Quent Capital's portfolio in Q1 2026, its #227 holding.
  • Quent Capital first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Pfizer position peaked at $921K in Q4 2022.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.